Evidence map›Paper›PMID 36309741›Full record

ArticleRespiratory research2022

End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation.

Norimichi Akiyama, Tomoyuki Fujisawa, Tatsuya Morita, Takafumi Koyauchi, Yoshinobu Matsuda, Masanori Mori, Mitsunori Miyashita, Ryo Tachikawa, Keisuke Tomii, Hiromi Tomioka and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Norimichi AkiyamaDepartment of Pulmonary Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, 426-8677, Fujieda, Japan.
Tomoyuki FujisawaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, 431-3192, Hamamatsu, Japan. fujisawa@hama-med.ac.jp.
Tatsuya MoritaPalliative and Supportive Care Division, Seirei Mikahahara General Hospital, Kita-ku, 3453, 433-8558, Mikatahara, Hamamatsu, Japan.
Takafumi KoyauchiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, 431-3192, Hamamatsu, Japan.
Yoshinobu MatsudaClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, 591-8555, Sakai, Osaka, Japan.
Masanori MoriPalliative and Supportive Care Division, Seirei Mikahahara General Hospital, Kita-ku, 3453, 433-8558, Mikatahara, Hamamatsu, Japan.
Mitsunori MiyashitaDepartment of Palliative Nursing, Health Sciences, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, 980-8575, Sendai, Miyagi, Japan.
Ryo TachikawaDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-minamimachi, 650-0047, Kobe City, Hyogo, Japan.
Keisuke TomiiDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-minamimachi, 650-0047, Kobe City, Hyogo, Japan.
Hiromi TomiokaDepartment of Respiratory Medicine, Kobe City Medical Center West Hospital, 4, 2-chome, Ichibancho, Nagata-ku, 653-0013, Kobe, Japan.
Satoshi HagimotoDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake- cho, 489-8642, Seto, Aichi, Japan.
Yasuhiro KondohDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake- cho, 489-8642, Seto, Aichi, Japan.
Yoshikazu InoueClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, 591-8555, Sakai, Osaka, Japan.
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, 431-3192, Hamamatsu, Japan.
Hamamatsu University School of Medicine · JPKobe City Medical Center General Hospital · JPNational Kinki Chuo Hospital for Chest Disease · JPSeirei Mikatabara General Hospital · JPTosei General Hospital · JPFujieda Municipal General Hospital · JPKobe City Medical Center West Hospital · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute exacerbation (AE) is a major cause of death in patients with idiopathic pulmonary fibrosis (IPF). AE-IPF patients require optimal palliative care; however, the real-world clinical situations are poorly understood. We aimed to survey the palliative care received by AE-IPF patients, especially with respect to opioid use for dyspnea and the end-of-life discussions (EOLd).

methodsSelf-administered questionnaires were dispatched to 3423 of the certified pulmonary physicians in Japan. They were asked to report a care report form of one patient each with AE-IPF who died very recently about opioid use for dyspnea and EOLd. We further explored the factors associated with the early use of opioids for dyspnea.

resultsAmong the 3423 physicians, 1226 (35.8%) returned the questionnaire with the report forms of 539 AE-IPF patients. Of 539 AE-IPF patients, 361 (67.0%) received opioids for dyspnea. Of the 361 patients, 72 (20.0%) received opioids during the initial treatment with an intention of recovery (early use), while 289 (80.0%) did when the recovery was deemed impossible. EOLd was held before the onset of AE in 124 patients (23.0%); however, the majority of patients had EOLd after the admission for AE-IPF. EOLd before the onset of AE was significantly associated with the early use of opioids.

conclusionIn terminally ill AE-IPF patients, opioids are usually administered when the recovery is deemed impossible, and EOLd are rarely held before the onset of AE. Further studies are warranted on the efficacy of opioids for dyspnea and the appropriate timing of EOLd.

Indexed as

Idiopathic Pulmonary FibrosisTerminal CareAnalgesics, OpioidDisease ProgressionDyspneaHumansLungRetrospective StudiesAnalgesics, OpioidAcute exacerbationEnd-of-life discussionIdiopathic pulmonary fibrosisPalliative care

Identifiers

PMID36309741
PMCPMC9617351
OpenAlexW4307812807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.